Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk

Asia Pacific Journal of Clinical Nutrition

Volumn 15, Issue SUPPL. 1, 2006, Pages 55-62

  Caterson, Ian D ^a   Finer, Nick ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Obesity; Orlistat; Pharmacotherapy; Rimonabant; Sibutramine

Indexed keywords

ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR DISEASE; HUMAN; OBESITY; REVIEW; RISK FACTOR; SAFETY; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HUMANS; LACTONES; OBESITY; PIPERIDINES; PYRAZOLES; RISK FACTORS; SAFETY; TREATMENT OUTCOME;

EID: 33750602705     PISSN: 09647058     EISSN: 09647058     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. World Health Organisation. Obesity and overweight. Available from http://www.who.int/ dietphysicalactivity/media/en/gsfs_obesity.pdf. Accessed on 13.7.06.
2. st Century. N Engl J Med 2005; 352: 1138-1145.
3. Cameron AJ, Welborn TA, Zimmet PZ, Dunstan DW, Owen N, Slamon J, Dalton M, Jolley D, Shaw JE. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aus 2003; 178: 427-432.
4. Wang Y, Mi J, Shan X-y, Wang QJ, Ge K-y. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes advance online publication 2 May 2006
5. Després JP. Intra-abdominal obesity: An untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Invest 2006; 29 (Suppl to no.3): 77-82.
6. th July 2006.
7. th July 2006.
8. Caterson ID. Weight Management. Australian Prescriber 2006; 29: 43-47.
9. O'Brian PE, Dixon JB. The management of obesity: surgery. In: Kopelman PG, Caterson ID, Dietz WH, eds. Clinical obesity in adults and children. Blackwell Publishing 2005; 394-406.
10. Proietto J, Baur LA. Management of obesity. Med J Aust 2004; 180: 474-480
11. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev 1999; 20: 68-100.
12. Blundell JE, Gillett A. Control of food intake in the obese. Obes Res 2001; 9 (Suppl 4): 263S-70S.
13. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WHM, Van Gaal LF, STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356: 2119-2125.
14. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care 2004; 27: 155-161.
15. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group. l. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
16. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
17. Shaw K, O'Rourke P, Del Mar C, Kenardy J. Psychological interventions for overweight or obesity. Cochrane Database of Systematic Reviews 2005, issue 2.
18. Wilding J, Finer N. Obesity and risk of myocardial infarction: the INTERHEART study. Lancet 2006; 367: 1053.
19. World Health Organization, International Association for the Study of Obesity & International Obesity Task Force. The Asia-Pacific perspective: Redefining obesity and its treatment. Available from: http://www.iotf.org/ asiapacific. Accessed on 16.07.06.
20. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from: http://www.idf.org Accessed on 16.07.06
21. American Association of Clinical Endocrinologists & American College of Endocrinology. AACE/ACE position statement on the prevention, diagnosis and treatment of obesity. Available from: http://www.aace.com/pub/ pdf/ guidelines/obesityguide.pdf. Accessed on 14th July 2006.
22. Tuthill A, Slawik H, O'Rahilly S, Finer N. Psychiatric comorbidities in patients attending specialist obesity services in the UK. QJM 2006; 99: 317-325
23. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension.A 1-year, double-blind, placebo-controlled, multicentre trial. Arch Intern Med 2000; 160: 2185-2191.
24. Smith IG, Goulder MA, Sibutramine clinical study 1047 team. Randomised, placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Prac 2001; 50: 505-512.
25. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-2120.
26. Broom I. Thinking around abdominal obesity and cardiovascular risk. Br J Diabetes Vasc Dis 2006; 6: 58-61.
27. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Kopperschaar HPF, Krempf M, European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-173.
28. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
29. Gelfand EV, Cannon CP. Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47: 1919-1926.
30. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. J Am Med Assoc 2006; 295: 761-775.
31. Van Gaal LF, Rissanen AM, Scheen AJ, Zeigler O, Rössner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
32. Deprés JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidaemia. N Engl J Med 2005; 353: 2121-2134.
33. Scheen A. Rimonabant in patients with Type 2 diabetes: Results from the RIO-Diabetes trial. Late breaking abstracts. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association, June 10-14th 2005, San Diego.
34. Pi-Sunyer X, Després JP, Scheen A, Van Gaal L. Improvement of metabolic parameters with rimonabant beyond the effect attributable to weight loss alone: Pooled 1-year data from the RIO (Rimonabant in Obesity and Related Disorders) program. J Am Coll Cardiol 2006; 47 (Suppl 1): 362A, abstract 849.
35. Halford JCG. Obesity drugs in clinical development. Curr Opin Invest Drugs 2006; 7: 312-318.
36. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (Exendin-4) on glycaemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
37. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated Type 2 diabetes patients. Obesity Res 2004; 12: 661-668.
38. Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M. Effect of pramlintide on satiety and food intake in obese subjects and subjects with Type 2 diabetes. Diabetologica 2005; 48: 838-848.
39. Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Méd 1947; 30:339-40.
40. Després JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl 2006; 8 (Suppl B): B4-12.